Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
23
YBGJ Quote, Financials, Valuation and Earnings
Last price:
$0.0500
Seasonality move
:
1070.83%
Day range:
$0.0497 - $0.0497
52-week range:
$0.0310 - $1.3700
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.07x
P/B ratio:
--
Volume:
1K
Avg. volume:
33.3K
1-year change:
-80.27%
Market cap:
$6M
Revenue:
$604.7K
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingYubo International Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Yubo International Biotech has an estimated downside of -- from its current price of $0.0497.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $0.0497.
Fair Value
-
According to the consensus of 0 analysts, Yubo International Biotech has -- downside to fair value with a price target of -- per share.
YBGJ vs. S&P 500
-
Over the past 5 trading days, Yubo International Biotech has overperformed the S&P 500 by 1.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Yubo International Biotech does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Yubo International Biotech revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Yubo International Biotech reported revenues of $3.5K.
Earnings Growth
-
Yubo International Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Yubo International Biotech reported earnings per share of -$0.01.
Enterprise value:
6M
EV / Invested capital:
--
Price / LTM sales:
13.07x
EV / EBIT:
--
EV / Revenue:
13.25x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$20.7K
Return On Assets:
-70.03%
Net Income Margin (TTM):
-282.62%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-11737.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $370K | $653.1K | -- | $428.5K | -- | |
| Gross Profit | $242.6K | $431.6K | $20.7K | $344.1K | -- | |
| Operating Income | -$1.7M | -$575.9K | -$1.9M | $6.4K | -$532.8K | |
| EBITDA | -$1.7M | -$487.6K | -$1.8M | $53.5K | -$483.2K | |
| Diluted EPS | -$0.01 | -$0.01 | -$0.02 | $0.00 | -$0.01 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $1.2M | $777.8K | $712.3K | $724K | |
| Total Assets | -- | $4.4M | $3.7M | $1.9M | $1.7M | |
| Current Liabilities | -- | $2.3M | $3M | $2.9M | $4.5M | |
| Total Liabilities | -- | $4.1M | $4.4M | $3M | $4.7M | |
| Total Equity | -- | $222.3K | -$658.1K | -$1.1M | -$3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $24.9K | -$870.1K | -$963.4K | $5.1K | -$92.6K | |
| Cash From Investing | -$57.8K | -- | $118.4K | -- | $36.5K | |
| Cash From Financing | -- | $669.2K | $1M | -- | $25.4K | |
| Free Cash Flow | -$32.9K | -$870.1K | -$963.4K | $5.1K | -$92.6K | |
YBGJ
Sector
Market Cap
$6M
--
Price % of 52-Week High
3.63%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
-80.27%
--
Beta (5-Year)
2.982
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.0499
200-day SMA
Sell
Level
$0.4213
Bollinger Bands (100)
Sell
Level
0.0238 - 0.2438
Chaikin Money Flow
Sell
Level
-12M
20-day SMA
Sell
Level
$0.0639
Relative Strength Index (RSI14)
Sell
Level
39.2994
ADX Line
Buy
Level
3.6062
Williams %R
Buy
Level
-82.0136
50-day SMA
Sell
Level
$0.0686
MACD (12, 26)
Sell
Level
-0.0098
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
4.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.8832)
Sell
CA Score
(Annual)
Level (-8.0796)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (1)
Sell
Ohlson Score
Level (17.543)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.
Stock Forecast FAQ
In the current month, YBGJ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The YBGJ average analyst price target in the past 3 months is --.
-
Where Will Yubo International Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Yubo International Biotech share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Yubo International Biotech?
Analysts are divided on their view about Yubo International Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Yubo International Biotech is a Sell and believe this share price will rise from its current level to --.
-
What Is Yubo International Biotech's Price Target?
The price target for Yubo International Biotech over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is YBGJ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Yubo International Biotech is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of YBGJ?
You can purchase shares of Yubo International Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Yubo International Biotech shares.
-
What Is The Yubo International Biotech Share Price Today?
Yubo International Biotech was last trading at $0.0500 per share. This represents the most recent stock quote for Yubo International Biotech. Yesterday, Yubo International Biotech closed at $0.0497 per share.
-
How To Buy Yubo International Biotech Stock Online?
In order to purchase Yubo International Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
